Literature DB >> 22221829

Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy.

Kazuna Takeda1, Shotaro Kanao, Tomohisa Okada, Masako Kataoka, Takayuki Ueno, Masakazu Toi, Hiroshi Ishiguro, Yoshiki Mikami, Kaori Togashi.   

Abstract

OBJECTIVE: To evaluate inter-observer agreement and the predictive value of tumor size measurements using MRI for breast cancer under neoadjuvant chemotherapy (NAC) by comparing the measurements of the longest diameters (LD), total enhanced volumes (TEV) and washout volumes (WOV).
METHODS: Thirty-seven female breast cancer patients were prospectively enrolled from August 2008 to October 2010. Two of these patients had locally advanced disease. MRI examinations were acquired within 2 weeks before and after NAC. Interim scans were also conducted in 30 patients. Tumor resection was undertaken within 2 weeks after the cessation of NAC. MRI images were independently measured for LD, TEV and WOV by two experienced radiologists. Inter-observer agreement was evaluated using concordance correlation coefficients (CCCs). Tumor sizes after NAC were evaluated relative to their initial sizes for early prediction of a pathological complete response (pCR).
RESULTS: The CCCs were 0.93 (CI: 0.90-0.95) for LD, 0.98 (CI: 0.97-0.98) for TEV and 0.99 (CI: 0.991-0.996) for WOV. All measurements had high inter-observer agreement, but the CCCs were significantly increased in the aforementioned order (P<0.0001). WOV measured after the completion of chemotherapy had significant discriminating ability (P=0.0056) when evaluated using receiver operating characteristic analysis, and was found to be superior to LD (P=0.045). The average WOV size was significantly smaller in pCR cases than in non-pCR cases (P=0.016).
CONCLUSION: Computer-aided detection-generated tumor volumes had significantly higher inter-observer concordance than conventional LD measurements. WOV measurements had the highest concordance, and WOV could better predict pCR after NAC at smaller tumor sizes.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22221829     DOI: 10.1016/j.ejrad.2011.12.013

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.

Authors:  Florentia Peintinger; Bruno Sinn; Christos Hatzis; Constance Albarracin; Erinn Downs-Kelly; Jerzy Morkowski; Rebekah Gould; W Fraser Symmans
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

2.  Automated Semi-Quantitative Analysis of Breast MRI: Potential Imaging Biomarker for the Prediction of Tissue Response to Neoadjuvant Chemotherapy.

Authors:  Matthias Dietzel; Clemens Kaiser; Katja Pinker; Evelyn Wenkel; Matthias Hammon; Michael Uder; Barbara Bennani Baiti; Paola Clauser; Rüdiger Schulz-Wendtland; Pascal Baltzer
Journal:  Breast Care (Basel)       Date:  2017-08-29       Impact factor: 2.860

3.  Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation.

Authors:  A P Nayate; J G Dubroff; J E Schmitt; I Nasrallah; R Kishore; D Mankoff; D A Pryma
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-12       Impact factor: 3.825

4.  Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer: a retrospective study.

Authors:  Ayane Yamaguchi; Maya Honda; Hiroshi Ishiguro; Masako Kataoka; Tatsuki R Kataoka; Hanako Shimizu; Masae Torii; Yukiko Mori; Nobuko Kawaguchi-Sakita; Kentaro Ueno; Masahiro Kawashima; Masahiro Takada; Eiji Suzuki; Yuji Nakamoto; Kosuke Kawaguchi; Masakazu Toi
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

5.  Evaluation of Breast Cancer Size Measurement by Computer-Aided Diagnosis (CAD) and a Radiologist on Breast MRI.

Authors:  Ji Yeon Park
Journal:  J Clin Med       Date:  2022-02-22       Impact factor: 4.241

6.  The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review.

Authors:  M B I Lobbes; R Prevos; M Smidt; V C G Tjan-Heijnen; M van Goethem; R Schipper; R G Beets-Tan; J E Wildberger
Journal:  Insights Imaging       Date:  2013-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.